Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.819904
Title: New innovations in endoscopic therapy
Author: Alzoubaidi, Durayd
ISNI:       0000 0004 9359 8610
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2020
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Barrett’s oesophagus (BE) is the pre-cancerous condition that leads to oesophageal adenocarcinoma (OAC). The progression of BE from intestinal metaplasia (IM) to dysplasia and OAC occurs in only a few patients. Once dysplasia and intramucosal cancer (IMC) has developed, these patients carry a significant risk of developing OAC. Despite significant advances in treatment modalities in the past decade, there still remains a high mortality rate with only a small number of patients alive at five years from diagnosis. Successful intervention at an early stage of the disease has been shown to have desirable outcomes. Historically, surgical intervention with oesophagectomy in patients with early disease has shown to achieve curative outcomes. Oesophagectomy by experienced surgeons in high volume tertiary referral centres still carries a significant mortality rate (2-3%). The development of minimally invasive endoscopic therapeutic modalities such as radiofrequency ablation (RFA), endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have revolutionised the management of patient with early oesophageal neoplasia with great outcomes and acceptable complication rates. These modalities have now been endorsed by various international guidelines; however despite current treatment modalities there still exists a group of patients that do not respond adequately to available treatment modalities and therefore this thesis and the chapters that follow will examine the new treatment modalities for the management of patients with early oesophageal neoplasia and will test the hypothesis that patients with early oesophageal neoplasia can be successfully treated with minimally invasive endoscopic therapy. This thesis will outline the use of a new endoscopic resection modality (EMR Captivator device) with a new ablative technique (Cryoablation) that utilises cold therapy rather than the conventional heat therapy (RFA). This thesis will also outline new quality indicators in endoscopic therapy of early oesophageal neoplasia, which was developed, in order to unify endoscopic therapy in the UK. It is well known that endoscopic therapy can result into adverse events such as bleeding during or/and after the procedure. Currently haemostatic modalities exits but not always effective and limited by the site of the bleed and skills of the operator. Hemospray, is a new haemostatic powder that is increasingly used internationally. This thesis will outline the creation and development of the international Hemospray registry, and study Hemospray in various pathologies.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.819904  DOI: Not available
Share: